[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-stroke":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,262,0,25,[9,56,86,112,140,158,190,221,250,271,290,319,342,372,389,413,445,470,501,522,547,569,592,625,645],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100444268","phase-2-treatment-of-acute-ischemic-stroke-remedy2-trial-100444268",false,"NCT05065216","Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","Phase 2\u002F3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","ReMEDy2","Inclusion Criteria:\n\n1. Participant is between 18 and 90 years of age inclusive.\n2. Participant weight is 40 kg to 166 kg inclusive.\n3. Participant to be randomized and treatment initiated within 24 hours of last known normal\u002FAIS stroke onset.\n4. Participant has NIHSS ≥5 and ≤15 at approximately the time of randomization. This criterion also applies to participants who meet the following conditions:\n\n   * The participant initially presents with an NIHSS score below 5 but clinically worsens, including cases of progressing stroke \u002F stroke-in-evolution, resulting in a subsequent persistent NIHSS score of ≥5 and ≤15; and\n   * Participant meets all other inclusion and exclusion criteria, including repeat brain imaging to rule out hemorrhagic transformation.\n5. Participant had a pre-morbid mRS score of 0 to 1 (mRS score prior to AIS) as stated by participant or participant's representative.\n6. If participant has received fibrinolytic treatment for AIS within 4.5 hours of last know normal\u002FAIS stoke onset and at least 6 hours after completing fibrinolytic treatment, and the participant meets all of the following criteria:\n\n   * Participant's initial NIHSS score prior to fibrinolytics was ≤15; and\n   * At least six hours after fibrinolytics, the participant has NIHSS score of ≥5 and ≤15 with a persistent deficit; and\n   * The participant's NIHSS score showed less than a 4-point improvement, or worsened, after receiving fibrinolytics; and\n   * Participant meets all other inclusion and exclusion criteria including repeat brain imaging to rule out hemorrhagic transformation.\n7. Participant and\u002For legally authorized representative is able to provide informed consent.\n8. Participant is willing and able to comply with the study protocol, in the Investigator's judgment.\n\nExclusion Criteria:\n\n1. At screening, or with repeat imaging (see Inclusion 4 and 6), participant has imaging confirmed hemorrhage stroke.\n2. Participant has image findings with symptomatic large vessel occlusion at one or more of the following locations: Intracranial carotid I\u002FT\u002FL or M1 segment MCA, vertebral or basilar artery (BA).\n3. Participant has large core of established infarction defined as ASPECTS 0-5.\n4. Participant has or will receive MT for their current AIS.\n5. Participant has suspected or confirmed extracranial arterial dissection.\n6. Participant has imaging findings and\u002For symptoms consistent with a brain stem or cerebellar stroke. Posterior cerebral artery strokes without any associated brain stem or cerebellar involvement are allowable.\n7. Participant has any recorded SBP \\\u003C100 mmHg or MAP \\\u003C65 mmHg; MAP = DBP + \\[1\u002F3 (SBP - DBP)\\] (measured with noninvasive BP cuff type monitor) after stroke symptom onset and prior to randomization.\n8. Participant is currently prescribed angiotensin-converting enzyme inhibitor (ACEi) and is unable or unwilling to convert to another antihypertensive pharmacological treatment through Day 29 ±1 day (8 days after last treatment).\n9. Participant is currently prescribed an ACEi, and the last dose of the ACE inhibitor medication is reported to have been taken \\\u003C 24 hours before start of IV study drug infusion as stated by participant or participant's representative.\n10. Participant has a history of clinically significant allergic reactions such as angioedema or anaphylaxis requiring hospitalization.\n11. Participant has a diagnosis or suspected diagnosis of hereditary angioedema (HAE) or is taking or prescribed medications commonly used as prophylaxis\u002Ftreatment of HAE, such as C1-esterase inhibitors (Cinryze, Berinert, Ruconest, Haegarda), Danazol, kallikrein inhibitors (Ecallantide, Berotralstat, Lanadelumab), Bradykinin B2 Receptor Antagonists (Icatibant), or other medication designed to influence the kallikrein-kinin system.\n12. Life expectancy estimated at ≤1 year prior to enrollment.\n13. Participant has clinical evidence of an active infection at the time of enrollment requiring parenteral treatment or hospitalization to monitor or manage the infection.\n\n    NOTE: Treatment of uncomplicated infections with oral antibiotics would not be an exclusion (for example, the treatment of uncomplicated urinary tract infections or sinus infections with oral antibiotics would not be exclusionary).\n14. Participant has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).\n15. Participant is pregnant or nursing. NOTE: Participants who agree to stop nursing may be considered for inclusion at the discretion of the Investigator.\n16. Participants of child-bearing potential must agree to use medically acceptable contraceptive measures to prevent pregnancy. All participants of childbearing potential (defined as sexually mature participants who have had menses within the preceding 24 months and have not undergone permanent sterilization methods such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) must have a negative serum pregnancy test performed locally at screening. Participants of childbearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization. If participating in sexual activity that could lead to pregnancy, participants must use 2 reliable methods (1 per partner is acceptable) of contraception simultaneously while receiving protocol-specified medication and during the study follow-up period.\n\n    Participants participating in sexual activity must agree to use, or for their partner to use highly effective birth control methods (those with a failure rate of less than 1% per year when used consistently and correctly) until they have completed the study (after the Day 90 visit). Such methods include:\n    * Combined (estrogen and progesterone containing) hormonal oral, intravaginal, or transdermal contraception associated with the inhibition of ovulation\n    * Progesterone-only oral, injectable, or implantable hormonal contraception associated with the inhibition of ovulation\n    * Intrauterine device (IUD)\n    * Intrauterine hormone-releasing system (IUS)\n    * Bilateral tubal occlusion\n    * Vasectomized partner\n    * Sexual abstinence Participants who are not of reproductive potential (who have been postmenopausal for more than 24 consecutive months or have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) are not required to use contraception.\n\n    Participants are prohibited from sperm donation. NOTE: A negative serum pregnancy test will be documented during screening if a participant is of child-bearing potential.\n17. Participant is currently participating in or has participated in a study using an investigational device or drug or received an investigational drug or investigational use of a licensed drug within 30 days prior to screening.\n18. Participant does not have sufficient venous access for infusion of study treatment or blood sampling.\n19. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.\n20. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.","ALL","18 Years","90 Years",{"count":22,"type":23},728,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE2","PHASE3","This is a Phase 2\u002F3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.",[30,31,32],"Acute Stroke","Ischemic Stroke","Stroke",[34,35,36,37,38,39,40,41,42],"acute","ischemic","stroke","AIS","tPA","LVO","MT","KLK1","Kallikreins","RECRUITING","2026-08-19",{"date":46,"type":47},"2026-08-21","ACTUAL",{"date":49,"type":47},"2021-11-07",{"date":51,"type":23},"2026-12",{"name":53,"class":54},"DiaMedica Therapeutics Inc","INDUSTRY",86,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":12,"sex":18,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100652962","ai-driven-health-management-to-prevent-ischemic-stroke-in-high-risk-adults-100652962","NCT07779668","AI-Driven Health Management to Prevent Ischemic Stroke in High-Risk Adults","Intelligent Early Warning of Ischemic Cerebrovascular Disease Based on Multi-Source Data Fusion and Demonstration of Tiered Prevention and Control in Beijing","AI-ExpoStroke","Inclusion Criteria:\n\n* Age 30 years or older, with no restriction on sex. Permanent resident of Beijing. No previously diagnosed stroke based on prospective community screening. Identified as being at high risk of stroke by the AI-ExpoStroke model in combination with the established stroke \"8+2\" high-risk factors.\n\nAble to comply with study follow-up and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of ischemic stroke or hemorrhagic stroke. Severe cognitive impairment. Severe organic disease, including malignant tumors, heart failure of NYHA class III or higher, renal failure, or other severe conditions.\n\nPsychiatric or language impairment that prevents completion of study questionnaires or follow-up.\n\nInability to obtain complete follow-up data or unwillingness to permit access to relevant study data.","30 Years","80 Years",{"count":67,"type":23},26000,[69],"NA","This study will evaluate whether an artificial intelligence (AI)-driven dynamic health management strategy can help prevent ischemic stroke in adults at high risk of stroke. Participants will be identified through community-based screening in Beijing using the AI-ExpoStroke model together with established stroke risk factors.\n\nCommunities will be randomly assigned to either an AI-driven health management group or a usual community-based health management group. Participants in the AI-driven group will receive continuous health management supported by a digital platform, mobile applications or WeChat-based tools, wearable-device data when available, personalized health guidance, and remote support from community health care providers. Participants in the usual-care group will receive routine community health services, including health examinations, health education, chronic disease follow-up, and medication guidance.\n\nParticipants will be followed for 36 months. The main goal is to determine whether AI-driven health management reduces the occurrence of first-ever ischemic stroke. The study will also evaluate transient ischemic attacks, stroke-related disability, mortality, control of major vascular risk factors, adherence to health management, and health economic outcomes.",[31],[73,74,75],"Artificial Intelligence","Stroke Prevention","Primary Prevention","NOT_YET_RECRUITING","2026-08-18",{"date":46,"type":47},{"date":80,"type":23},"2026-08-31",{"date":82,"type":23},"2029-12-31",{"name":84,"class":85},"Xuanwu Hospital, Beijing","OTHER",{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100514299","early-closure-of-left-atrial-appendage-for-patients-with-atrial-fibrillation-and-ischemic-stroke-despite-anticoagulation-therapy-100514299","NCT05976685","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy","ELAPSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization.\n* Recent (≤3 months) symptomatic ischemic stroke.\n* Active and ongoing anticoagulation therapy at stroke onset assessed based on medical history (i.e. any therapeutic oral anticoagulation therapy \\[Vitamin K antagonist\u002FDOAC according to prescription recommendations for AF; inadequate low-dose DOAC therapy allowed for inclusion\\] not stopped\u002Fpaused for \\>48 hours due to any reason, i.e. medical intervention or non-adherence).\n* Active or planned long-term therapy with DOAC\n\nExclusion Criteria:\n\n* Contraindications to DOAC therapy\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Stroke due to: Ipsilateral intra\u002Fextracranial high-grade stenosis, Isolated lacunar stroke, Other well-defined stroke aetiologies (i.e., endocarditis, vasculitis, Reversible Cerebral Vasoconstriction Syndrome \\[RCVS\\], Posterior Reversible Encephalopathy Syndrome \\[PRES\\], cerebral sinus venous thrombosis)\n* Previous persistent foramen ovale or atrial septum defect closure.\n* Rheumatic heart disease\n* Severe heart valve disease that requires treatment (severe aortic stenosis or regurgitation, severe mitral stenosis or regurgitation).\n* Contraindications for TEE (relevant esophageal varices, esophageal stricture, history of esophageal cancer).\n* Cardiac or non-cardiac surgical procedure within 30 days of randomization\n* Enrolled in another investigation of a cardiovascular device or investigating secondary prevention therapy.\n* Severely reduced Left Ventricular Ejection Fraction (LVEF) \\\u003C30%.\n* Severe renal impairment as described in the summary of medicinal product characteristics for the chosen DOAC (e.g. rivaroxaban, apixaban and edoxaban creatinine clearance \\\u003C15 ml\u002Fmin; dabigatran creatinine clearance \\\u003C30 ml\u002Fmin).\n* Hypertrophic cardiomyopathy\n* Intracardiac tumor\n* Ventricular thrombus\n* Acute cardiac decompensation\n* LAA is obliterated or surgically ligated\n* Persistent proximal LAA thrombus despite 4 weeks of anticoagulation (if a proximal thrombus in the LAA is found, anticoagulation with vitamin K antagonist (INR 2.5-3.5) may be started, and if the thrombus disappears, the patient may be eligible for LAAO)\n* Pregnancy or breastfeeding (pregnancy test in urine or blood to be performed at screening for women of childbearing potential)",{"count":95,"type":23},482,[69],"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%\u002Fyear. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is \"breakthrough\" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \\>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \\>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.",[31,99],"Atrial Fibrillation",[32,101,102],"Direct oral anticoagulation","Left atrial appendage occlusion",{"date":104,"type":47},"2026-08-20",{"date":106,"type":47},"2024-05-01",{"date":108,"type":23},"2028-06-01",{"name":110,"class":85},"Insel Gruppe AG, University Hospital Bern",31,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100642716","phase-2-a-phase-2b-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642716","NCT07645560","A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2","MASTRE-2","Inclusion Criteria:\n\n1. Age 18-80 years.\n2. Ischemic stroke onset within the past 14 days.\n3. Unilateral, supratentorial ischemic stroke confirmed by CT or MRI.\n4. Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n5. NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points.\n6. Written informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant).\n2. History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease.\n3. Midline shift or parenchymal mass effect on cranial CT or other imaging.\n4. CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum).\n5. Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n6. Pre-stroke mRS ≥ 2.\n7. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment.\n8. Pregnant or breastfeeding women, or women planning pregnancy within 90 days.\n9. Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up.\n10. Concomitant malignant tumor or severe systemic disease with life expectancy \\\u003C 90 days.\n11. Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.",{"count":121,"type":23},60,[26],"This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.",[31],[126,127,128,129,130],"ishchemic stroke","Lesion network mapping","Continuous theta-burst stimulation","Motor function","Neuronavigation","2026-08-16",{"date":77,"type":47},{"date":134,"type":23},"2026-08-26",{"date":136,"type":23},"2027-12-30",{"name":138,"class":85},"Beijing Tiantan Hospital",1,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":139},"100642075","phase-3-a-phase-3-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642075","NCT07645586","A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3","MASTRE-3",{"count":148,"type":23},584,[27],"This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.",[31],[126,127,128,129,130],{"date":77,"type":47},{"date":155,"type":23},"2026-10-01",{"date":136,"type":23},{"name":138,"class":85},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100600521","comparison-of-four-channel-functional-electrical-stimulation-vs-one-channel-electrical-stimulation-on-moderate-armhand-paresis-in-subacute-stroke-patients-100600521","NCT07098572","Comparison of Four-Channel Functional Electrical Stimulation vs. One-Channel Electrical Stimulation on Moderate Arm\u002FHand Paresis in Subacute Stroke Patients","Efficacy of EMG-triggered Four-Channel Functional Electrical Stimulation vs. Cyclic One-Channel Electrical Stimulation on Moderate Arm\u002FHand Paresis in Subacute Stroke Patients. A Randomized Controlled Single Blinded Multicenter Study","MKES2","Inclusion Criteria:\n\n* First-time ischemic stroke with moderate arm paresis (Motricity Index - UE Sum-Score ≥ 40 ≤ 77 points) (Collin \\& Wade, 1990)\n* Early to late subacute phase (7 days - 6 months) (Bernhardt et al., 2017)\n* Existing ADL ability before the event (ICF d5 self-care, d6 domestic life, extent of problem ≤1 points) (WHO, 2001)\n* Age ≥18 - 99 years\n* Signed and dated ICF before the start of any study-specific procedure.\n\nExclusion Criteria:\n\n* Lack of compliance with any inclusion criteria\n* Implanted defibrillators, brain stimulators, pacemakers, medication pumps\n* Therapy-resistant epilepsy\n* Fever or infectious diseases\n* Inflammatory or tumorous skin diseases in the stimulation area,\n* Thromboses or vein inflammations\n* Severe contractures of the affected extremity\n* Wounds in the stimulation area\n* Pregnancy\n* Known allergic reactions to components of the investigational medical device\n* Unstable psychological status\n* Participation in other pharmacological clinical investigations within four weeks prior to enrolment\n* Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study","99 Years",{"count":168,"type":23},44,[69],"This study will compare two treatments that may help participants recover after having suffered from stroke. Persons who experience weakness or paralysis of their arms\u002Fhands will be randomly placed in one of two groups. Each receives treatment five times a week for three weeks. One group will be treated with electrostimulation following a cyclic pattern (control treatment), the other group will be treated with electrostimulation triggered by nerve signals (i.e. stimulation starts when they deliberately try to move their arm (investigational treatment). Before and after the three weeks and additionally 12 weeks later, the ability to move the arm and hand will be documented with standardized tests.",[172,31],"Moderate Arm Paresis",[174,175,176,177,178,179],"Arm Paresis","Hand Paresis","Stiwell Profes","Electrostimulation","Ischemic stroke","Rehabilitation","2026-08-13",{"date":182,"type":47},"2026-08-14",{"date":184,"type":47},"2025-08-12",{"date":186,"type":23},"2028-01",{"name":188,"class":54},"MED-EL Elektromedizinische Geräte GesmbH",3,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":20,"enrollmentInfo":198,"targetDuration":200,"studyType":201,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":139},"100652127","photon-counting-ct-for-intracranial-stent-assessment-100652127","NCT07769814","Photon-counting CT for Intracranial Stent Assessment","Evaluation of Ultra-high Resolution Photon-counting CT Angiography for Intracranial Stent Assessment: A Prospective Diagnostic Study With Digital Subtraction Angiography as Reference Standard","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients with previously implanted intracranial arterial stents;\n3. Undergoing follow-up CTA examination;\n4. Available imaging data for analysis.\n\nExclusion Criteria:\n\n1. Severe motion artifacts;\n2. Poor contrast enhancement;\n3. Incomplete clinical or imaging data.","5 Years",{"count":199,"type":23},200,"4 Years","OBSERVATIONAL","Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions. Evaluation of stent patency and detection of in-stent restenosis are essential during follow-up. Digital subtraction angiography (DSA) remains the reference standard for intracranial stent assessment; however, it is an invasive procedure associated with potential complications and radiation exposure. Conventional CT angiography may be limited by stent-related artifacts, including blooming artifact and beam-hardening effects, which can impair accurate evaluation of the stent lumen.",[204,205,206,31],"Intracranial Atherosclerotic Disease (ICAD)","Intracranial Arterial Stenosis","Stent Restenosis",[208,209,210,211,212],"Photon-counting CT","Ultra-high-resolution CT","In-stent restenosis","Intracranial stent","CT angiography","2026-08-12",{"date":77,"type":47},{"date":216,"type":47},"2026-01-07",{"date":218,"type":23},"2029-01-07",{"name":220,"class":85},"Xin Lou",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":139},"100651848","dentate-targeted-temporal-interference-stimulation-for-post-stroke-dysphagia-100651848","NCT07766668","Dentate-Targeted Temporal Interference Stimulation for Post-Stroke Dysphagia","Individualized Transcranial Temporal Interference Stimulation Targeting the Dentato-Thalamo-Cortical Pathway for Post-Stroke Dysphagia: A Randomized, Double-Blind, Sham-Controlled Trial","DENTIS-PSD","Inclusion Criteria:\n\n* Age 18 to 80 years\n* First-ever unilateral supratentorial ischemic stroke confirmed by computed tomography or magnetic resonance imaging\n* Stroke onset 14 to 90 days before randomization\n* Oropharyngeal dysphagia confirmed by videofluoroscopic swallowing study, with a worst Penetration-Aspiration Scale score of 3 to 7 during prespecified standardized bolus trials\n* Medically stable and able to remain seated during stimulation and swallowing rehabilitation\n* Able to follow one-step commands, directly or with supported communication\n* Written informed consent provided by the participant or a legally authorized representative\n\nExclusion Criteria:\n\n* Brainstem or primary cerebellar stroke, bilateral cerebral infarction, previous symptomatic stroke, intracranial hemorrhage, or progressive neurological disease\n* Pre-stroke dysphagia, structural oropharyngeal disease, previous treatment for head and neck cancer, or another condition that independently explains dysphagia\n* Tracheostomy, current mechanical ventilation, uncontrolled pneumonia, severe hypoxemia, or hemodynamic instability\n* History of epilepsy, seizure after the index stroke, unexplained loss of consciousness, or current use of medication considered to confer an unacceptable seizure risk\n* Intracranial metallic material, implanted electronic device, cochlear implant, or another contraindication to transcranial temporal interference stimulation, magnetic resonance imaging, or transcranial magnetic stimulation\n* Severe cognitive, behavioral, or language impairment that prevents participation despite supported communication\n* Pregnancy or breastfeeding\n* Major scalp disease at the planned electrode sites\n* Participation in another interventional clinical trial\n* Any other condition considered unsafe or unsuitable by the investigator",{"count":230,"type":23},88,[69],"The goal of this clinical trial is to learn whether individualized transcranial temporal interference stimulation can improve swallowing in adults with swallowing difficulties after an ischemic stroke. It will also evaluate the safety and tolerability of this stimulation. The main questions it aims to answer are:\n\n* Does active temporal interference stimulation combined with swallowing rehabilitation improve swallowing safety more than sham stimulation combined with the same rehabilitation?\n* What side effects or medical problems occur during and after the stimulation?\n\nResearchers will compare active stimulation with sham stimulation, which uses the same equipment but does not deliver sustained therapeutic stimulation.\n\nParticipants will:\n\n* Receive active or sham stimulation for 30 minutes per session, 5 days per week for 2 weeks\n* Receive the same task-specific swallowing rehabilitation after each stimulation session\n* Undergo swallowing assessments, brain imaging, and neurophysiological testing\n* Attend follow-up assessments 4 and 12 weeks after treatment",[234,31],"Deglutition Disorders",[36,236,237,238,239,240,241],"dysphagia","temporal interference stimulation","cerebellar dentate nucleus","swallowing rehabilitation","neuroplasticity","randomized controlled trial","2026-08-09",{"date":182,"type":47},{"date":245,"type":23},"2026-09-01",{"date":247,"type":23},"2030-03-01",{"name":249,"class":85},"Zhejiang University",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":258,"targetDuration":260,"studyType":201,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":189},"100651472","a-study-to-monitor-safety-and-effectiveness-of-approved-jj-medtech-devices-in-the-treatment-of-participants-with-ischemic-stroke-100651472","NCT07760649","A Study to Monitor Safety and Effectiveness of Approved J&J MedTech Devices in the Treatment of Participants With Ischemic Stroke","A Post-market Observational Study to Monitor Safety and Effectiveness in the Treatment of Patients With Ischemic Stroke Using Commercially Approved J&J MedTech Devices Optimized for Neurovascular Thrombectomy","POSEIDON","Inclusion criteria:\n\n* Participant is 18 years of age or older at the time of consent\n* Informed Consent has been provided by the participant or the participants' legally authorized representative (LAR)\n* Participants with angiographic confirmation of acute ischemic stroke\n* A clinical decision has been made to treat the participant with an eligible Johnson \\& Johnson MedTech neuro-thrombectomy device independently and prior to enrollment in the study\n\nExclusion criteria:\n\n* Known pregnancy, as evidenced by positive pregnancy test for women of childbearing potential or breast feeding\n* Current involvement in an investigational (drug, device, etcetera) clinical study that may confound study endpoints. Sponsor approval is required prior to enrollment",{"count":259,"type":23},5000,"90 Days","The purpose of this study is to collect medical information to monitor the ongoing safety of the J\\&J MedTech devices and to understand how well they work when routinely used to treat participants with acute ischemic stroke (a condition caused by a blocked blood vessel in the brain).",[31],"2026-08-07",{"date":213,"type":47},{"date":266,"type":23},"2026-08-10",{"date":268,"type":23},"2030-12-31",{"name":270,"class":54},"Neuravi Limited",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":139},"100651207","comparison-between-non-contrast-magnetic-resonance-angiography-and-carotid-doppler-in-cerebrovascular-stroke-100651207","NCT07756775","Comparison Between Non-contrast Magnetic Resonance Angiography and Carotid Doppler in Cerebrovascular Stroke","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Clinically diagnosed ischemic stroke or transient ischemic attack (TIA).\n* Imaging performed within 7-14 days of symptom onset.\n* Hemodynamically stable and suitable for magnetic resonance imaging (MRI).\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke.\n* Previous carotid artery stenting.\n* Contraindications to MRI, including:\n\n  * Non-MRI-compatible pacemakers or other MRI-incompatible implants.\n  * Cochlear implants.\n  * MRI-incompatible metallic orthopedic implants.\n  * Severe claustrophobia.",{"count":199,"type":23},"This prospective observational study aims to compare the diagnostic performance of non-contrast magnetic resonance angiography (NC-MRA) and carotid Doppler ultrasonography in the evaluation of carotid artery disease among patients with ischemic cerebrovascular stroke or transient ischemic attack. A total of 200 adult patients presenting to Sohag University Hospital will undergo both imaging modalities. The study will assess the agreement between NC-MRA and carotid Doppler in detecting and grading carotid artery stenosis according to the NASCET criteria, with the goal of evaluating the clinical utility of each technique and optimizing imaging strategies for the assessment of cerebrovascular stroke.",[31,280,281],"Transient Ischemic Attack","Carotid Artery Stenosis (Symptomatic and Asymptomatic)",{"date":283,"type":47},"2026-08-11",{"date":285,"type":47},"2026-07-20",{"date":287,"type":23},"2027-03-20",{"name":289,"class":85},"Sohag University",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100650673","impact-of-presenting-symptoms-on-treatment-time-and-outcomes-in-acute-ischemic-stroke-100650673","NCT07750847","Impact of Presenting Symptoms on Treatment Time and Outcomes in Acute Ischemic Stroke","Impact of Presenting Symptoms in Ischemic Stroke Onset on Time Treatment Window and Clinical Outcome of Acute Ischemic Stroke Patients","Inclusion Criteria:\n\n* Patients aged \\>= 18 years at the time of presentation.\n* Confirmed clinical diagnosis of acute first-ever ischemic stroke supported by objective neuroimaging findings via history case taking and emergency CT or MRI scans.\n* Hospital admission initiated within 48 hours of initial symptom onset.\n* Informed consent provided, signed, and dated by the patient or a legally authorized proxy representative.\n\nExclusion Criteria:\n\n* In-hospital stroke onset.\n* Diagnosis of a Transient Ischemic Attack (TIA) or presenting stroke mimics (e.g., complex migraines, severe hypoglycemia, conversion disorders, status epilepticus).\n* Pre-existing severe functional disability prior to the index stroke event, established as a baseline pre-stroke Modified Rankin Scale (mRS) score \\> 2.\n* Co-morbid advanced or terminal medical or neurological or psychiatric conditions with a documented clinical life expectancy of less than 6 months.\n* Incomplete medical charts, structural data gaps, or formal withdrawal on baseline assessment or on hospital stay assessment before discharge.",{"count":298,"type":23},120,"This observational study aims to understand how the specific symptoms a person experiences at the start of an acute ischemic stroke affect how quickly they receive treatment and how well they recover.\n\nIn stroke care, rapid treatment is critical because delayed intervention can lead to more severe disability or death. Patients who experience \"high urgency\" or classic stroke symptoms, such as sudden paralysis, severe facial drooping, or loss of speech, tend to arrive at the emergency room very quickly because these signs are easily recognized by bystanders. In contrast, patients who experience \"low urgency\" or vague symptoms, such as dizziness, numbness, visual changes, or a new-onset headache, often delay seeking medical care. Because these vague symptoms can mimic other medical conditions, they can lead to delayed diagnosis and longer waiting times for specific stroke treatments.\n\nThe researchers will observe 120 adult patients admitted for a first-ever acute ischemic stroke. Participants will be categorized into two groups based on whether their initial stroke symptoms were highly urgent or vague. The study will track and compare both groups to evaluate:\n\n* The time it takes for patients to arrive at the hospital and receive intervention therapies.\n* The patients' level of physical disability and independence in daily activities.\n* The patients' cognitive function.\n* The total length of the hospital stay, complication rates, and overall survival. Participants will be monitored from the time of their hospital admission through their discharge. To measure long-term recovery and functional outcomes, patients will also complete follow-up assessments at two weeks, one month, two months, and three months after leaving the hospital.",[301,31,32],"Acute Ischemic Stroke",[303,304,305,306,307,308,309],"Presenting Symptoms","Time Treatment Window","Clinical Outcome","Onset-to-Door Time","Reperfusion Therapy","High Urgency Symptoms","Door-to-Needle Time","2026-08-05",{"date":312,"type":47},"2026-08-06",{"date":314,"type":23},"2026-09",{"date":316,"type":23},"2027-10",{"name":318,"class":85},"Assiut University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":341,"locationsCount":4},"100650648","impact-of-stroke-unit-care-on-acute-stroke-outcomes-100650648","NCT07750860","Impact of Stroke Unit Care on Acute Stroke Outcomes","Impact of Stroke Unit Care on Outcome of Acute Stroke Patients","Inclusion Criteria:\n\n* Patients aged ≥ 18 years at the time of presentation.\n* Confirmed clinical diagnosis of acute first ever stroke (either ischemic or hemorrhagic) supported by objective neuroimaging findings via history case taking and emergency CT or MRI scans.\n* Hospital admission initiated within 48 hours of initial symptom onset.\n* Informed consent provided, signed, and dated by the patient or a legally authorized proxy representative.\n\nExclusion Criteria:\n\n* Diagnosis of a Transient Ischemic Attack (TIA) or presenting stroke mimics (e.g., complex migraines, severe hypoglycemia, conversion disorders, status epilepticus).\n* Pre-existing severe functional disability prior to the index stroke event, established as a baseline pre-stroke Modified Rankin Scale (mRS) score \\> 2.\n* Co-morbid advanced or terminal medical or neurological or psychiatric conditions with a documented clinical life expectancy of less than 6 months.\n* Incomplete medical charts, structural data gaps, or formal withdrawal on baseline assessment or on hospital stay assessment before discharge.",{"count":327,"type":23},140,"This observational study is designed to evaluate and compare the recovery outcomes of patients who have experienced their first acute stroke. Specifically, it looks at how receiving care in a specialized Stroke Unit compares to receiving care in a conventional hospital neurology ward.\n\nResearchers will observe 140 adult patients admitted to Assiut University Hospital within 48 hours of their stroke symptoms starting. Patients will be observed in two distinct groups of 70 based on their admission setting:\n\n* Stroke Unit Care: Patients in this group receive care from a specialized, multi-professional team (including vascular neurologists, stroke nurses, neuro-physiotherapists, and clinical pharmacists). They undergo continuous heart and vital sign monitoring for the first 24 to 48 hours, participate in early physical activity protocols, and follow strict guidelines for swallowing checks, temperature control, and blood sugar management.\n* Conventional Ward Care: Patients in this group receive standard medical care and general nursing management. Their vital signs are checked during routine shifts, and physical therapy is provided only when specifically requested on a case-by-case basis.\n\nThe study will track the patients' progress by measuring their independence in daily activities, physical disability levels, and cognitive (thinking) skills. Assessments will happen when they are discharged from the hospital, and then again at 2 weeks, 1 month, 2 months, and 3 months after they go home to evaluate their overall recovery, complications, and mortality rates.",[30,31,330],"Hemorrhagic Stroke",[332,333,334,335,336,337],"Stroke Unit","Functional Outcome","Modified Rankin Scale (mRS)","Barthel Index","National Institutes of Health Stroke Scale (NIHSS)","Montreal Cognitive Assessment (MoCA)",{"date":312,"type":47},{"date":314,"type":23},{"date":316,"type":23},{"name":318,"class":85},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100630767","continuous-dual-aspiration-technique-with-zoom-system-for-stroke-100630767","NCT07491952","Continuous Dual Aspiration Technique With Zoom System for Stroke","Clinical Evaluation of Continuous Dual Aspiration Technique With Zoom System for Stroke (ADAPT 2.0)","ADAPT 2 0","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure\n3. Pre-stroke mRS 0-2\n4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use\n\nExclusion Criteria:\n\n1. Subjects with a life expectancy of less than 6 months\n2. Female subject who is known to be pregnant at time of admission\n3. Any intracranial hemorrhage in the qualifying head CT or MRI\n4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).\n5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System\n6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study",{"count":351,"type":23},750,"This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).",[31,30],[36,355,356,357,358,359,360,361,362,363],"thrombectomy","Zoom","aspiration","reperfusion","mRS","ADAPT","continuous","dual aspiration","Zoom System",{"date":263,"type":47},{"date":366,"type":47},"2026-03-24",{"date":368,"type":23},"2030-06-01",{"name":370,"class":54},"Imperative Care, Inc.",17,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":4,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":378,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":384,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":387,"locationsCount":4},"100650443","nuvox-expanded-access-100650443","NCT07748299","NuvOx Expanded Access","* Inclusion Criteria:\n\n  1. Patients must have a condition that is serious or immediately life-threatening.\n  2. Patients must have exhausted other treatment options or are ineligible to participate in ongoing clinical trials.\n  3. The potential benefits of treatment with NanO₂ must outweigh the potential risks, as determined at the discretion of the treating physician and NuvOx.\n* Exclusion criteria:\n\n  1. Providing NanO₂ for the requested use will interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the use.\n\n     * A request will be evaluated against the criteria of 21 CFR 312.305(a) and 312.310(a).\n\n       * NuvOx will consider the totality of available information, including applicable nonclinical and clinical experience, the patient's condition, and the treating physician's rationale for use.","EXPANDED_ACCESS","NanO₂ is an investigational drug being studied by NuvOx Therapeutics. It has not been approved by the U.S. Food and Drug Administration (FDA) for any use. This record describes a way for a patient's own doctor to request NanO₂ for that patient outside of a clinical trial, through a pathway called \"expanded access\" (sometimes called \"compassionate use\").\n\nThis option may be considered for patients who have a serious or life-threatening illness, who have already tried other available treatments, and who cannot join an ongoing NanO₂ clinical trial. NuvOx's RESTORE study in glioblastoma has finished enrolling patients, and NuvOx does not currently have any other NanO₂ study open for enrollment in the United States.\n\nUnder this pathway, the patient's treating physician - not NuvOx - applies to the FDA and manages the patient's care. NuvOx's role is to review each request, and if approved, provide the drug and the regulatory information the FDA needs to evaluate it. Each request is reviewed individually, and approval is not guaranteed.",[381,382,31,383],"Glioblastoma","Respiratory Distress Syndrom","Hypoxic Conditions","AVAILABLE","2026-08-03",{"date":310,"type":47},{"name":388,"class":54},"NuvOx LLC",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":412},"100603652","timing-of-anticoagulation-after-emergency-endovascular-therapy-for-acute-ischemic-stroke-with-atrial-fibrillation-100603652","NCT07139301","Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation","Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation：a Randomised Controlled Trial","TIMERS-1","Inclusion Criteria:\n\n1. Aged 18 years or over.\n2. Clinical diagnosis of large vessel occlusion acute ischemic stroke.\n3. Emergency endovascular treatment was performed within 24 hours of stroke onset.\n4. Atrial fibrillation (including paroxysmal, persistent or permanent atrial fibrillation), confirmed by at least one of the following:\n\n   1. 12-lead ECG recording\n   2. Inpatient ECG telemetry\n   3. Prolonged ECG monitoring (e.g. Holter monitor)\n   4. Previously established diagnosis of atrial fibrillation verified by medical records.\n5. CT or MRI demonstrating one of the following findings:\n\n   1. No hemorrhagic transformation;\n   2. Hemorrhagic infarction type 1 (HI1), defined as small petechiae along the margins of the infarct (Heidelberg classification);\n   3. Hemorrhagic infarction type 2 (HI2), defined as confluent petechiae within the infarcted area without space-occupying effect (Heidelberg classification).\n6. Time from stroke onset to randomization was within 72 hours.\n7. Written informed consent obtained from the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Atrial fibrillation due to reversible causes (e.g. thyrotoxicosis, pericarditis, recent surgery, or myocardial infarct).\n2. Contraindication to the use of direct oral anticoagulants (DOACs):\n\n   1. Known allergy or intolerance to both factor Xa inhibitors and direct thrombin inhibitors;\n   2. Definite indication for vitamin K antagonist (VKA) treatment (e.g. mechanical heart valve, valvular atrial fibrillation);\n   3. Severe renal impairment (defined as creatinine exceeding 1.5 times of the upper limit of normal range) and significant hepatic dysfunction (defined as ALT or AST \\> twice the upper limit of normal range) ;\n   4. Concomitant use of medications with significant interactions with DOACs, including azole antifungals, HIV protease inhibitors, or strong CYP3A4 inducers;\n   5. Baseline platelet count \\\u003C 100 x 109\u002FL;\n   6. History of coagulopathy or systemic hemorrhage.\n3. Prior DOAC use within 48 hours of stroke onset, or recent treatment with vitamin K antagonist (VKA) leading to INR ≥1.7 at randomization.\n4. Pregnant or breastfeeding women, or positive pregnancy test at admission.\n5. History of major surgery or severe trauma within 1 month prior to stroke onset.\n6. History of active bleeding within 1 month prior to stroke onset (e.g. gastrointestinal bleeding, urinary tract bleeding).\n7. Dual antiplatelet therapy at baseline, or strong likelihood of requiring dual antiplatelet therapy during the trial.\n8. Evidence of cerebral amyloid angiopathy.\n9. CT or MRI evidence of non-stroke pathology likely to account for the presenting clinical symptoms (e.g. mass lesion, encephalitis).\n10. Modified Rankin scale (mRS) score \\> 1 prior to stroke onset.\n11. Inability to complete the 90-day follow-up.\n12. Currently participating in another drug clinical trial.\n13. Any other reason deemed by the investigator to make the patient unsuitable for participation in the trial.",{"count":398,"type":23},438,[69],"This study evaluates the safety and efficacy of early versus delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischemic stroke related to atrial fibrillation after emergency endovascular therapy (EVT).",[31,99],[403,101,404,405,32],"Endovascular Therapy","Therapy initiation","Randomized Controlled Trial",{"date":310,"type":47},{"date":408,"type":47},"2025-09-04",{"date":80,"type":23},{"name":411,"class":85},"Capital Medical University",40,{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":24,"phases":423,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100601520","phase-4-lacunar-stroke-hyperacute-clinical-utilization-of-novel-approach-regimens-rt-pa-vs-dapt-randomised-clinical-trial-100601520","NCT07111559","Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","A Multicenter Randomized Controlled Trial Comparing Tissue Plasminogen Activator With Dual Antiplatelet Therapy for Patients With Hyperacute Single Perforating Artery Infarction","LACUNAR-tPA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Acute ischemic stroke within 4.5 hours from onset. If onset time is unknown because of impaired consciousness or aphasia, use the \"last known well\" time.\n* A single perforating-artery infarct on brain MRI:\n\nlocated in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.\n\n* No disability in daily life before the stroke (modified Rankin Scale ≤ 1).\n* National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Antithrombotic therapy considered inappropriate because of active bleeding, low platelet count, or similar conditions.\n* Any contraindication to intravenous rt-PA, without blood pressures.\n* ≥ 50 % stenosis or occlusion of the artery responsible for the stroke \\* (see note below).\n* Diseases that require anticoagulation (e.g., atrial fibrillation, deep-vein thrombosis) \\*\n* Inability to take medicine orally.\n* Any other reason judged by the principal investigator or co-investigators to make participation inappropriate.\n\nNote: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with \\* must be judged using the similar examinations that each site normally performs before rt-PA administration.",{"count":422,"type":23},500,[424],"PHASE4","The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:\n\nIs a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?\n\nResearchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).\n\nParticipants will:\n\nTake a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.",[427,32,31],"Lacunar Stroke",[429,430,431,432,433,434],"rt-PA","tissue-plasminogen activator","DAPT","dual antiplatelet therapy","minor stroke","lacunar stroke","2026-08-02",{"date":437,"type":47},"2026-08-04",{"date":439,"type":47},"2025-08-01",{"date":441,"type":23},"2029-03-31",{"name":443,"class":85},"Nippon Medical School",29,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":453,"targetDuration":4,"studyType":24,"phases":455,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":469},"100621167","a-pivotal-study-evaluating-safety-and-effectiveness-of-adaptative-tip-catheter-in-patients-with-acute-ischemic-stroke-100621167","NCT07367100","A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke","A Prospective, First in Human Pivotal Study to Evaluate the Adaptive Tip Catheter Used to Treat Acute Ischemic Stroke Patients During Mechanical Thrombectomy","PHAST","Inclusion criteria:\n\n* Age greater than or equal to (\\>=) 18 years, less than or equal to (\\\u003C=) 90 years, at the time of consent\n* Signs and symptoms consistent with the diagnosis of acute ischemic stroke in the anterior circulation that can be treated with endovascular thrombectomy approaches\n* Endovascular treatment can be initiated (defined as access puncture) within 24 hours from time last known well\n* Baseline National Institutes of Health Stroke Scale (NIHSS) score \\>= 6\n* Baseline Alberta Stroke Program Early CT Score (ASPECTS) \\>= 3\n* A signed and dated Informed Consent Form (ICF) or Investigator Statement for emergency procedure (as allowed according to country regulations and approved by EC) has been obtained\n\nExclusion criteria:\n\n* Known pregnancy, as evidenced by positive pregnancy test for women of childbearing potential or breast feeding\n* Life expectancy less than (\\\u003C) 90 days prior to stroke onset\n* Known hemorrhagic diathesis disorder, coagulation factor deficiency or oral anticoagulant therapy with known International Normalized Ratio (INR) greater than (\\>) 3.0\n* Clinical symptoms and\u002For CT\u002FMRI evidence suggestive of bilateral stroke or stroke in multiple vascular territories, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior\u002Fposterior circulation)\n* Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic\n* Computed Tomography\u002F Magnetic Resonance Imaging (CT\u002FMRI) evidence of recent\u002Ffresh hemorrhage\n* Baseline CT or MRI showing mass effect\n* Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Patients in observational, natural history, and\u002For epidemiological studies not involving intervention are eligible\n* Cerebral catheter angiographic evidence of pre-existing arterial disease, that potentially impacts treatment and\u002For outcome (for example, vasculitis)\n* Any occlusion or stenosis that limits device access to the target area (for example, carotid dissection, tandem occlusions) or requiring acute stenting to achieve access\n* Cerebral catheter angiographic evidence of multiple cerebrovascular occlusions, defined as occlusions in more than one vessel not downstream from each other (for example, bilateral anterior circulation, anterior\u002Fposterior circulation)\n* Excessive vascular access tortuosity that will likely prevent endovascular access with the adaptive tip catheter (ATC)\n* Baseline expanded thrombolysis in cerebral infarction (eTICI) \\> 1",{"count":454,"type":23},74,[69],"The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.",[31],[459,301,460],"Large Vessel Occlusion","Mechanical Thrombectomy","2026-07-30",{"date":463,"type":47},"2026-07-31",{"date":465,"type":47},"2026-02-02",{"date":467,"type":23},"2027-07-31",{"name":270,"class":54},15,{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":500},"100559977","phase-4-safety-and-efficacy-of-intravenous-thrombolysis-in-patients-with-ischemic-stroke-and-direct-oral-anticoagulants-intake-100559977","NCT06571149","Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke on Treatment With Direct Oral Anticoagulants: DO-IT - The DOAC Intravenous Thrombolysis Trial","DO-IT","Inclusion Criteria:\n\n* Informed consent (deferred consent when possible according to national legislation)\n* AIS eligible to receive intravenous alteplase\u002Ftenecteplase as per standard of care disabling according to the judgement of the treating physician\n* DOAC ingestion within 48 hours prior to enrollment, or patient with an ongoing prescription of DOAC but exact time point of last intake is unknown.\n* Either\n\n  * Can be randomized within 4 hours 15 minutes and treated within 4 hours 30 minutes of last known well time OR\n  * MRI showing a pattern of \"DWI-FLAIR-mismatch\", i.e. acute ischemic lesion visibly on DWI (\"positive DWI\") but no marked parenchymal hyperintensity visible on FLAIR (\"negative FLAIR\") indicative of an acute ischemic lesion ≤4.5 hours of age AND Treatment can be started within 4.5 hours of symptom recognition (e.g., awakening).\n\nExclusion Criteria:\n\n* Contra-indications to IVT by the current standard of care of the treating physicians with the exception of recent DOAC intake as specified above.\n* Intended reversal by specific or unspecific reversal agents\n* Pregnancy or lactating women. To be reasonable sure to exclude women with ongoing pregnancy, women are not considered of childbearing potential if they fulfill the following criteria\n\n  * Age \\> 55 years OR\n  * Age \\\u003C 55 years and at least 12 months since last menstrual period OR\n  * Have had a documented surgical sterilization\n* Patient \\\u003C 18 years of age (since the benefit of IVT is unproven in this population)\n\nSince the benefit of IVT might be smaller in patients in which additional endovascular treatment is planned, the investigators will cap patients with intended mechanical thrombectomy at 20% of the trial population. If this number is reached, the following additional exclusion criterion will be applied:\n\n* Intended treatment with endovascular reperfusion strategies",{"count":479,"type":23},906,[424],"DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute ischemic stroke (AIS) with recent (within the last 48 hours) intake of direct oral anticoagulant (DOAC). For this purpose, 906 adult participants experiencing an AIS with recent DOAC intake will be enrolled at several high-volume international stroke centers and randomly assigned in a ratio of 1:1 to one of two treatment arms: (1) IVT and standard of care\u002Fbest medical treatment or (2) standard of care\u002Fbest medical treatment. The DO-IT trial is a definitive test of the hypothesis that IVT is superior to standard of care for achieving better outcome at 90 days in AIS participants with recent DOAC intake.",[31],[484,485,486,487,488,489,490,491,492,493],"DOAC","NOAC (Novel Oral Anticoagulants)","Anticoagulation","r-tPA (tissue-type plasminogen activator)","Alteplase","Tenecteplase","Rivaroxaban","Apixaban","Dabigatran","Edoxaban",{"date":385,"type":47},{"date":496,"type":47},"2025-03-14",{"date":498,"type":23},"2029-04-30",{"name":110,"class":85},102,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":139},"100619521","basilar-artery-occlusion-chinese-endovascular-registry-in-patients-with-large-core-infarct-100619521","NCT07345702","Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct","Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)","BAOCHE-LC","Inclusion Criteria:\n\n1. Age ≥18 years, men or women.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.\n4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n\nExclusion Criteria:\n\n1. Subjects with occlusions in both anterior and posterior circulation.\n2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset\u002Flast known well time, or missing major treatment information including whether EVT was performed).\n4. Baseline NIHSS score \\\u003C6.\n5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n6. Missing follow-up outcomes at 90 days.\n7. Any other condition judged by investigators to substantially affect analysis or interpretation.",{"count":510,"type":23},518,"This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.",[513,31,514],"Basilar Artery Occlusion","Large Core Infarct","2026-07-28",{"date":461,"type":47},{"date":518,"type":47},"2026-01-31",{"date":520,"type":23},"2026-10-31",{"name":84,"class":85},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":529,"maxAge":4,"enrollmentInfo":530,"targetDuration":532,"studyType":201,"phases":4,"briefSummary":533,"conditions":534,"keywords":535,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":546},"100441721","antithrombotic-drug-use-in-patients-with-ischemic-stroke-and-microbleeds-100441721","NCT05032053","Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds","AIM-2","Inclusion Criteria:\n\n1. Patients diagnosed clinically as ischemic stroke;\n2. Age ≥ 40 years;\n3. Onset time ≤ 3 months;\n4. Informed consent was signed.\n\nExclusion Criteria:\n\n1. Patients with symptomatic intracranial hemorrhage;\n2. bleeding lesion \\> 10 mm was found on SWI;\n3. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;\n4. There are contraindications for antithrombotic drugs use;\n5. Serious systemic diseases;\n6. Refusal to sign informed consent or poor compliance.","40 Years",{"count":531,"type":23},3000,"1 Year","To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.",[31],[31,536,537,538],"microbleeds","Proteomics","antithrombotic drug",{"date":461,"type":47},{"date":541,"type":47},"2022-03-01",{"date":543,"type":23},"2027-12-01",{"name":545,"class":85},"Xijing Hospital",16,{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":554,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":555,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":568},"100584542","clinical-evaluation-of-new-biomarkers-for-ischemic-cerebrovascular-disease-100584542","NCT06890702","Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease","A Prospective Observational Cohort Study of Predictive Biomarkers Related With Ischemic Cerebrovascular Disease","Inclusion Criteria:\n\n* Ischemic cerebrovascular disease has been proved by clinical symptoms and imaging examinations,including transient ischemic attack, cerebral ischemic stroke, steal syndrome, chronic cerebral hypoperfusion, ect al.\n* sex and age-matched healthy individuals\n\nExclusion Criteria:\n\n* Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation)\n* With severe systemic disease, are expected to survive \\\u003C 3 months\n* Patients will not able to provide continuous follow-up information",true,{"count":556,"type":23},7000,"The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are:\n\nCan specific biomarkers help in identifying high-risk individuals before disease onset? Can these biomarkers predict disease progression and treatment response? Researchers will compare patients diagnosed with ICVD and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance.\n\nParticipants will:\n\nProvide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis.\n\nUndergo clinical imaging (CT, MRI, PET-CT) and functional assessments. Be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes.\n\nThis study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.",[31,559],"Ischemic Cerebrovascular Disease","2026-07-27",{"date":515,"type":47},{"date":563,"type":47},"2025-01-01",{"date":565,"type":23},"2038-01-01",{"name":567,"class":85},"Tongji Hospital",2,{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":575,"maxAge":65,"enrollmentInfo":576,"targetDuration":4,"studyType":24,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":139},"100649634","evaluation-of-clinical-efficacy-and-mechanism-of-hand-jing-well-acupoint-transcutaneous-electrical-stimulation-in-improving-post-stroke-cognitive-impairment-100649634","NCT07736885","Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment","Inclusion Criteria:\n\n1. Aged 35-80 years;\n2. Stroke duration within 2 weeks to 6 months post-onset;\n3. Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score \\\u003C 26;\n4. Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric\u002Fbehavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);\n5. No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;\n6. Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Unstable vital signs or life-threatening comorbidities;\n2. Implanted devices (cardiac pacemaker\u002Fdefibrillator, deep brain stimulator, etc.);\n3. History of epilepsy or epileptic seizures;\n4. Pregnant or lactating women;\n5. Concurrent use of other medications affecting cognitive function;\n6. Allergy to the study intervention device or history of serious adverse reactions;\n7. Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);\n8. Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.","35 Years",{"count":577,"type":23},70,[69],"This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.\n\nPurpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.\n\nWho can participate: Adults aged \\[35-80\\] who have had an ischemic stroke and now have mild to moderate cognitive impairment.\n\nWhat happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.\n\nPotential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.\n\nRisks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.",[581,31,582,583],"Post-Stroke Cognitive Impairment (PSCI)","Cognitive Dysfunction, Cognitive Disorder","Hemorrhagic Strokes","2026-07-26",{"date":461,"type":47},{"date":587,"type":23},"2026-08-15",{"date":589,"type":23},"2027-03-30",{"name":591,"class":85},"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":529,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":139},"100649262","msc-secretome-therapy-for-cognitive-recovery-after-subacute-ischemic-stroke-100649262","NCT07731087","MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke","Efficacy of Mesenchymal Stem Cell Secretome Therapy on Cognitive Recovery in Patients With Subacute Ischemic Stroke: A Pilot Randomized Controlled Trial Using qEEG, BDNF, and Interleukin-1β Evaluation","Inclusion Criteria:\n\n1. Age 40 to 75 years.\n2. Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging.\n3. Stroke onset between 7 days and 3 months before enrollment.\n4. Hemodynamically stable.\n5. Able to undergo a basic neuropsychological assessment.\n6. Mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment.\n7. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke.\n2. Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid.\n3. History of dementia before stroke or a major neurodegenerative disorder.\n4. Active infection, active autoimmune disease, active malignancy, severe renal failure, or severe liver failure.\n5. Uncontrolled epilepsy.\n6. Concurrent participation in another clinical trial.\n7. Contraindication to any study intervention or study procedure.","75 Years",{"count":577,"type":23},[69],"Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.",[31,604],"Post-Stroke Cognitive Impairment",[606,607,608,609,610,611,612,613,614,615,616,617],"Subacute ischemic stroke","Post-stroke cognitive impairment","Mesenchymal stem cell secretome","MSC secretome","Cognitive recovery","MoCA-Ina","Quantitative electroencephalography","qEEG","Brain-derived neurotrophic factor","BDNF","Interleukin-1 beta","IL-1β","2026-07-23",{"date":515,"type":47},{"date":621,"type":47},"2026-07-09",{"date":51,"type":23},{"name":624,"class":85},"Jumraini Tammasse",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":632,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":24,"phases":635,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":139},"100649150","phase-3-zastaprazan-for-the-prevention-of-upper-gi-bleeding-in-ischemic-stroke-100649150","NCT07730840","Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke","A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy of Zastaprazan in PrEventing Upper Gastrointestinal Bleeding in Patients With Transient Ischemic Attack or Ischemic Stroke Receiving Antiplatelet or Anticoagulant Therapy: ZEUS Trial","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Onset of transient ischemic attack (TIA) or ischemic stroke within 180 days prior to randomization\n3. Currently initiating or receiving, at the time of randomization, one of the following treatments, with an expected treatment duration of at least 3 weeks:\n\n   A. Dual antiplatelet therapy (DAPT) - aspirin in combination with one of the following: clopidogrel, ticagrelor, prasugrel, or cilostazol B. Oral anticoagulant therapy - a NOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) or warfarin\n4. Provision of written informed consent by the participant (or legally authorized representative)\n\nExclusion Criteria:\n\n1. Clinically significant peptic ulcer or gastrointestinal bleeding within 1 year prior to enrollment\n2. Moderate to severe hepatic impairment (e.g., diagnosis of cirrhosis or confirmed esophageal\u002Fgastric varices)\n3. Severe thrombocytopenia (platelet count \\\u003C50,000\u002FµL)\n4. End-stage renal disease requiring dialysis, or unstable renal function precluding safe anticoagulant dose adjustment (eGFR \\\u003C15 mL\u002Fmin\u002F1.73m²)\n5. Known hypersensitivity to potassium-competitive acid blockers (P-CABs) or to the investigational product\n6. History of major gastrointestinal surgery resulting in malabsorption, bowel obstruction, or inability to take oral medication\n7. History of osteoporotic fracture or fragility fracture\n8. Diagnosis of a condition requiring long-term, high-dose systemic corticosteroid therapy\n9. Diagnosis of a condition requiring long-term concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs)\n10. Pregnant or breastfeeding women\n11. Life expectancy of less than 6 months due to pre-existing comorbid conditions\n12. Current participation in another interventional clinical trial that could affect the results of this study\n13. Any condition that, in the investigator's judgment, precludes participation\n14. Participant or partner of childbearing\u002Freproductive potential who does not agree to use a medically acceptable method of contraception, or to abstain from sexual activity with risk of pregnancy, during the study period\n15. Currently receiving, or having received within 5 half-lives prior to randomization, a prohibited concomitant medication expected to interact with the investigational product (products containing atazanavir, nelfinavir, or rilpivirine)\n16. History of peptic ulcer complications, including bleeding, perforation, or stricture, regardless of timing\n17. Active bleeding at the time of enrollment, history of a coagulation disorder, or hemodynamic instability at the time of enrollment\n18. Known hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption","19 Years",{"count":634,"type":23},984,[27],"The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to answer is:\n\n\\- Does zastaprazan reduce the risk of upper gastrointestinal bleeding compared to placebo in these patients?\n\nResearchers will compare zastaprazan to a placebo (a look-alike tablet that contains no drug) to see if zastaprazan works to prevent upper gastrointestinal bleeding.\n\nParticipants will:\n\n* Take zastaprazan (20 mg) or a placebo once daily for the duration of the study, in addition to their prescribed antiplatelet or anticoagulant medication\n* Visit the study site regularly for safety monitoring, including vital signs, physical exams, and laboratory tests\n* Be monitored for any signs of gastrointestinal bleeding or other adverse events for up to approximately 3 years (including screening, treatment, and follow-up periods)",[31,280],{"date":515,"type":47},{"date":640,"type":23},"2026-10-15",{"date":642,"type":23},"2029-09-30",{"name":644,"class":85},"Asan Medical Center",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":4,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":24,"phases":654,"briefSummary":655,"conditions":656,"keywords":657,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":139},"100603345","stroke-120-action-trial-100603345","NCT07135310","STROKE 120 ACTION Trial","STROKE 120 ACTION: a National Cluster Randomized Controlled Trial","This trial will evaluate whether the STROKE 120 multifaceted intervention campaign can reduce the pre-hospital delay in AIS and increase the 4.5-hour arrival rate in 16 community units across 8 regions in China. We will select 2 community units from each region as the study sites and randomly divide the 2 community units within each region into the intervention group and the control group. The selection criteria for community units are listed as follows:\n\n1. The 2 participating community units in each region should each have a permanent population over 110,000 (people aged 60 years and above accounting for at least 15%), have similar demographic characteristics (e.g., age, gender, and education level), and have comparable local health policies (e.g., medical insurance policies, emergency system framework, stroke emergency map release, and stroke center quality control), economic levels, and public ability to recognize AIS.\n2. The participating hospitals in each community unit serve \\>90% of AIS patients within the community unit, have a well-established stroke center, and have comparable standardized treatment capabilities for AIS (including 4.5-hour hospital arrival rate of AIS, rate of using 120 emergency ambulances after AIS, and rate of IVT after AIS).\n3. The participating communities are capable of implementing STROKE 120 multifaceted intervention campaign within its community unit.\n4. To avoid cross-contamination, the physical distance between any two community units exceeds 20 kilometers.",{"count":653,"type":23},1696000,[69],"Stroke is the main cause of death and disability in China, but it is preventable and treatable. For the most common type, acute ischemic stroke (AIS), initiating reperfusion therapy with intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT) within several hours of the onset of symptoms can significantly improve the chances of surviving free of major disability, and earlier the intervention is given the better the outcome. Thus, whether patients can achieve timely arrived at hospital, ideally within the critical 4.5-hour golden window, is pivotal to achieving high rates of recanalization and optimal functional outcome. To this end, it is important to note that the overall pre-hospital delay for patients with AIS is currently 24 hours in China.\n\nWe plan to conduct STROKE 120 ACTION, a national cluster randomized controlled trial, to determine whether implementing a STROKE 120 multifaceted intervention campaign can reduce pre-hospital delay in AIS, increase the 4.5-hour hospital arrival rate, and improve survival, disability, and healthcare costs. The STROKE 120 ACTION trial will recruit 16 community units across 8 regions in China, with each region enrolling 2 community units with a residential population of at least 110,000 and comparable demographic characteristics. To avoid cross-contamination, the participating community clusters will maintain a physical distance of more than 20 kilometers. Within each region, the 2 community units will be randomly assigned at a 1:1 ratio to receive the intervention (12-month usual health policy plus STROKE 120 multifaceted intervention campaign; 3-month intensive period and 9-month maintenance period) or control (12-month usual health policy alone). The study outcomes and related data on incident AIS cases within each participating community unit will be collected after the implementation of STROKE 120 multifaceted intervention campaign (from month 1 to month 12 of multifaceted intervention campaign). The primary outcome is proportion of hospital arrival within 4.5 hours after symptom onset within participating community units. Secondary outcomes include time from onset to hospital admission, time from onset to action, use of 120 emergency ambulances, IVT, MT, total hospitalization costs, out-of-pocket costs, composite outcome of death or major disability (modified Rankin scale score \\[mRS\\] ≥3) at 3 months, ordinal 7-level mRS score at 3 months, all-cause mortality within 3 months. The sample size was calculated according to the following estimates: (1) a significance level of 0.05 for a 2-sided test; (2) statistical power of 85%; (3) 4.5-hour hospital arrival rate of 10% for AIS patients in control group; (4) 4.5-hour hospital arrival rate of 20% among AIS patients in intervention group; (5) intra-class correlation coefficient of 0.03; and (6) a 10% loss to follow-up. The estimated sample size is 3,312 incident AIS patients from 16 community units with an average cluster size of 207 patients per community unit. The annual incidence of AIS is 195 per 100,000 people, and the sample size of participants in each community unit will be 106,000. Thus, the total sample size of the present study will be 1,696,000 participants from 16 community units.\n\nThe STROKE 120 ACTION trial will address the critical issue of long pre-hospital delay in AIS in China, and provide profound implications for global stroke prevention and control strategies.",[31],[178,658,659],"Pre-hospital delay","Cluster-randomized trial",{"date":661,"type":47},"2026-07-21",{"date":663,"type":47},"2025-12-01",{"date":665,"type":23},"2027-02-28",{"name":667,"class":85},"Shanghai Minhang Central Hospital"]